Novavax raises revenue forecast on licensing deals
Novavax increased its annual revenue outlook to between $235 million and $275 million as it shifts focus toward licensing its protein-based platform. The company is leveraging a major partnership with Sanofi to drive growth while navigating a 76% decline in second-quarter vaccine sales.
X24 PerspectiveRelated Assets:
X24 Perspective